Multilineage Lymphoblastic Lymphoma as an Initial Presentation of Mixed Phenotype Acute Leukemia.

IF 0.7 Q4 HEMATOLOGY

Case Reports in Hematology Pub Date : 2023-01-01 DOI:10.1155/2023/3628712

Mako Ikeda, Wataru Nakahara, Mizuki Asako, Yuka Umeki, Yoshiki Matsuoka, Takuya Terakawa, Hitomi Matsunaga, Yuki Iwasa, Riko Saito, Yuki Iwama, Takahiro Matsui, Kazumasa Oka, Shuji Ueda

{"title":"Multilineage Lymphoblastic Lymphoma as an Initial Presentation of Mixed Phenotype Acute Leukemia.","authors":"Mako Ikeda, Wataru Nakahara, Mizuki Asako, Yuka Umeki, Yoshiki Matsuoka, Takuya Terakawa, Hitomi Matsunaga, Yuki Iwasa, Riko Saito, Yuki Iwama, Takahiro Matsui, Kazumasa Oka, Shuji Ueda","doi":"10.1155/2023/3628712","DOIUrl":null,"url":null,"abstract":"<p><p>Mixed phenotype acute leukemia (MPAL) is characterized by leukemic blasts that express markers of multiple lineages. Compared with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), MPAL is considered to have a poor treatment outcome. We report a case of MPAL T/myeloid not otherwise specified that was initially presented as multilineage lymphoblastic lymphoma and subsequently developed into leukemic MPAL. An acute lymphoblastic leukemia-based treatment regimen was ineffective, but azacitidine and venetoclax therapy resulted in hematological complete remission. Our case suggests that multilineage lymphoblastic lymphoma should be considered to be the same disease as MPAL, albeit with different clinical presentations. Optimal treatment for MPAL has not been established yet, but azacitidine and venetoclax therapy may be a potential approach.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985503/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2023/3628712","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Mixed phenotype acute leukemia (MPAL) is characterized by leukemic blasts that express markers of multiple lineages. Compared with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), MPAL is considered to have a poor treatment outcome. We report a case of MPAL T/myeloid not otherwise specified that was initially presented as multilineage lymphoblastic lymphoma and subsequently developed into leukemic MPAL. An acute lymphoblastic leukemia-based treatment regimen was ineffective, but azacitidine and venetoclax therapy resulted in hematological complete remission. Our case suggests that multilineage lymphoblastic lymphoma should be considered to be the same disease as MPAL, albeit with different clinical presentations. Optimal treatment for MPAL has not been established yet, but azacitidine and venetoclax therapy may be a potential approach.

Abstract Image

查看原文本刊更多论文

多系淋巴母细胞淋巴瘤是混合表型急性白血病的初始表现。

混合表型急性白血病(MPAL)的特点是白血病母细胞表达多个谱系的标记。与急性髓性白血病(AML)和急性淋巴细胞白血病(ALL)相比，MPAL被认为具有较差的治疗效果。我们报告一例MPAL的T/髓系未另有说明，最初表现为多系淋巴母细胞淋巴瘤，随后发展为白血病MPAL。急性淋巴细胞白血病为基础的治疗方案是无效的，但阿扎胞苷和venetoclax治疗导致血液学完全缓解。我们的病例提示，尽管临床表现不同，但多系淋巴母细胞淋巴瘤应被视为与MPAL相同的疾病。MPAL的最佳治疗方法尚未确定，但阿扎胞苷和venetoclax治疗可能是一种潜在的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Case Reports in Hematology HEMATOLOGY-

自引率

0.00%

发文量

审稿时长

13 weeks